Kura Oncology’s (KURA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $32.00 target price on the stock.

Several other equities analysts also recently issued reports on KURA. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the company from $26.00 to $19.00 in a report on Monday, October 14th. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a report on Monday, August 12th. UBS Group began coverage on Kura Oncology in a research note on Thursday. They issued a “buy” rating and a $27.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $28.83.

Kura Oncology Stock Performance

NASDAQ KURA opened at $17.51 on Thursday. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -7.85 and a beta of 0.84. The stock has a 50-day moving average of $19.34 and a 200 day moving average of $20.09. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. Kura Oncology has a twelve month low of $7.52 and a twelve month high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same period last year, the company earned ($0.53) EPS. The business’s quarterly revenue was up .0% compared to the same quarter last year. Sell-side analysts anticipate that Kura Oncology will post -2.46 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of KURA. Susquehanna Fundamental Investments LLC acquired a new stake in Kura Oncology during the first quarter worth about $507,000. Hennion & Walsh Asset Management Inc. lifted its holdings in Kura Oncology by 42.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 181,674 shares of the company’s stock valued at $3,875,000 after acquiring an additional 54,031 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Kura Oncology by 50.1% in the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after acquiring an additional 577,732 shares during the period. Vanguard Group Inc. increased its stake in Kura Oncology by 0.7% during the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after acquiring an additional 28,212 shares during the last quarter. Finally, Sofinnova Investments Inc. raised its position in Kura Oncology by 64.4% in the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.